Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR T cells with CMV vaccine

T cells engineered to express HIV-specific chimeric antigen receptors (CARs) represent a promising strategy to clear HIV-infected cells, but to date have not achieved clinical benefits. A likely hurdle is the limited T cell activation and persistence when HIV antigenemia is low, particularly during...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Min, Lim, Laura, Holguin, Leo, Han, Tianxu, Vyas, Vibhuti, Urak, Ryan, Miller, Aaron, Browning, Diana L., Echavarria, Liliana, Li, Shasha, Li, Shirley, Chang, Wen-Chung, Scott, Tristan, Yazaki, Paul, Morris, Kevin V., Cardoso, Angelo A., Blanchard, M. Suzette, Le Verche, Virginia, Forman, Stephen J., Zaia, John A., Burnett, John C., Wang, Xiuli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062763/
https://www.ncbi.nlm.nih.gov/pubmed/35573050
http://dx.doi.org/10.1016/j.omtm.2022.04.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062763/
https://www.ncbi.nlm.nih.gov/pubmed/35573050
http://dx.doi.org/10.1016/j.omtm.2022.04.007

Ejemplares similares